Elisabeth de Darkó
Nessuna posizione attualmente
Profilo
Elisabeth de Darkó served as the Chief Executive Officer of Valderm ApS from 2006 to 2014.
She also worked as the Director of Medical & Regulatory Affairs at Yamanouchi Nordic.
Precedenti posizioni note di Elisabeth de Darkó
| Società | Posizione | Fine |
|---|---|---|
| Yamanouchi Nordic | Direttore Tecnico/Scientifico/R&S | - |
Valderm ApS
 Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Valderm ApS
Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Health Technology |
| Yamanouchi Nordic |
- Borsa valori
- Insiders
- Elisabeth de Darkó
